A study of a GLP-1 medicine, semaglutide, in women going through menopause.

Recruiting now. Registry record last updated July 21, 2026.

Who can join: Adults 45 to 55, women only, are going through menopause.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 4.6 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor University of Colorado, DenverDrug semaglutideClass GLP-1 RASites 3 USEnrollment target 200

What this study is for

Primary condition: Menopause. Also studied in: Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular.

Full scientific study title: Focusing on the Menopausal Transition to Improve Mid-Life Women's Health.

Who can join

Age45 to 55SexFemaleBMIany to 30

Adults 45 to 55, women only, are going through menopause. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

aged 45-55
In the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18
No current use of hormone therapy or hormonal contraception
Presence of a uterus and at least one ovary in order to track menstrual patterns
Have a smartphone and broadband access adequate to accept telehealth appointments

Key exclusion criteria

Lack of broadband access (activity and survey data will be collected electronically whenever possible and some visits will be via telehealth)
Lack of regular menstrual periods in mid-reproductive life (ages 25-38) when not on hormones or not pregnant.
Pregnancy or actively trying to get pregnant
Inability to adhere to study protocol schedule
Untreated alcoholism

Where this trial is enrolling

This trial has 3 sites across 3 states. Contact a site coordinator directly to start screening.

Find a site near you

Colorado1 site

University of Colorado-School of Medicine
Aurora, Colorado

North Carolina1 site

University of North Carolina, School of Medicine
Chapel Hill, North Carolina
Chelsea A Grinnan, RN919-908-0010REI_research@med.unc.edu

Virginia1 site

Virginia Commonwealth University
Richmond, Virginia
Keila Najera, MPH804-221-5159Keila.najera@vcuhealth.org

Follow this trial

We email you if NCT06975111 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: March 1, 2026. Expected completion: October 1, 2030. Last updated on ClinicalTrials.gov: July 21, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.